Review Article
Evaluation of Transfusion Pyrexia: A Review of Differential Diagnosis and Management
Table 1
Immunosuppressive conditions with relative risk for TaGVHD.
| At risk groups of patients | |
| (1) Autologous bone marrow/stem cell transplant recipients | | (2) Allogeneic bone marrow/stem cell transplantrecipients | | (3) Hodgkin’s disease | | (4) B-cell malignancies (non-Hodgkin’s lymphoma, multiple myeloma, Waldenstrom’s macroglobulinemia, ALL) | | (5) Fludarabine, cladribine therapy | | (6) Directed donations from blood relatives | | (7) HLA matched platelets | | (8) Congenital immunodeficiency disorders (SCID, Wiskott-Aldrich) | | (9) Intrauterine transfusions | | (10) Granulocyte transfusions in infants | |
|
|